Therapy Areas
All Sessions
Resectable NSCLC
Advanced NSCLC
SCLC
Biomarkers
Drug Classes
Targeted Therapies
Immunotherapies
ADCs
Industry Sponsored
Featured Sessions
First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C
New Therapy Options in SCLC and AE Management
Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.
MDT-BRIDGE in Resectable and Borderline Resectable NSCLC
Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
Latest Advances in Frontline EGFR+ NSCLC
} 14 min
From Our Annual Summit
ILCS Sessions
Welcome & introduction
ctDNA-guided decisions in lung cancer: ready or not?
New standards in EGFR- and ALK-positive NSCLC
Other actionable genomic alterations, incl. HER2 and ROS1
Targeting (K)RAS with new compounds
The ADC wave: integrating new agents in NSCLC
Latest options in early-stage NSCLC: novel IO approaches for improved outcomes
New compounds and combinations for non-oncogene-addicted advanced NSCLC
The emerging role of T-cell engagers and ADCs in SCLC
Debate: which is the better choice in 1L ES-SCLC?
Panel: open questions & patient cases
Expert Insights
Webinars
2026 Year in Review
Learn more about the event →
2025 Approvals & Highlights
} 1 h 49 min
Targeted Therapies in NSCLC
} 1h 30 min
Immunotherapies in NSCLC
} 1h 47 min
Small Cell Lung Cancer
} 1h 35 min
The Reading Room
Articles & Research
South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in
Lenvatinib plus pembrolizumab gave a median PFS of 22.1 months in pretreated thymic carcinoma and B3 thymoma
A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival
SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide
Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC
MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells
Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC
Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling
KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC
VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries
Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up
Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial
Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2
Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE
Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC
Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC
KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC
TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC
ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational
Industry Sponsored
Featured Sessions
One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey
First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C
New Therapy Options in SCLC and AE Management
Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.
MDT-BRIDGE in Resectable and Borderline Resectable NSCLC
Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
Latest Advances in Frontline EGFR+ NSCLC
} 14 min
From Our Annual Summit
ILCS Sessions
Welcome & introduction
ctDNA-guided decisions in lung cancer: ready or not?
New standards in EGFR- and ALK-positive NSCLC
Other actionable genomic alterations, incl. HER2 and ROS1
Targeting (K)RAS with new compounds
The ADC wave: integrating new agents in NSCLC
Latest options in early-stage NSCLC: novel IO approaches for improved outcomes
New compounds and combinations for non-oncogene-addicted advanced NSCLC
The emerging role of T-cell engagers and ADCs in SCLC
Debate: which is the better choice in 1L ES-SCLC?
Panel: open questions & patient cases
Expert Insights
Webinars
2026 Year in Review
Learn more about the event →
2025 Approvals & Highlights
} 1 h 49 min
Targeted Therapies in NSCLC
} 1h 30 min
Immunotherapies in NSCLC
} 1h 47 min
Small Cell Lung Cancer
} 1h 35 min
The Reading Room
Articles & Research
South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in
Lenvatinib plus pembrolizumab gave a median PFS of 22.1 months in pretreated thymic carcinoma and B3 thymoma
A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival
SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide
Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC
MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells
Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC
Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling
KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC
VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries
Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up
Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial
Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2
Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE
Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC
Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC
KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC
TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC
ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational
Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update
First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg
Community indicators flagged high lung cancer incidence areas in California better than smoking alone
Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months
Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study
A papal diagnosis turns the world’s attention to its most diagnosed cancer
Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue
More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC
Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung
IASLC pathologists propose a grade 3 category for lung carcinoids with more than 10 mitoses
Four Austrian societies back a national, risk-adapted lung cancer screening programme
Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey
A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC
Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry
Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation
Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC
AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy
KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials
Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial